Agendia Announces Six Studies in Breast and Colon Cancer for Presentation at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

By Agendia, PRNE
Tuesday, May 31, 2011

AMSTERAM and IRVINE, California, June 1, 2011 -

Agendia, a commercial-stage molecular cancer diagnostics
company, announces today that it will present results from four completed and
one ongoing study, at the Annual Meeting of the American Society of Clinical
Oncology (ASCO). Agendia will publish the results of an additional study in
conjunction with the event. The meeting will be held from 3-7 June, 2011 at
McCormick Place in Chicago, IL.

Currently on the market in US and Europe, Agendia's Symphony(TM) suite of
molecular diagnostic breast cancer tests enables physicians to determine
whether a given breast cancer patient is likely to benefit from hormonal
therapy, chemotherapy and targeted therapies, thereby providing benefits over
existing treatment approaches for patients, physicians and payors.

Agendia's lead product, Mammaprint(R), is currently the only molecular
diagnostic breast cancer recurrence test available on the market to have
received FDA clearance. Agendia's product development pipeline includes a
further extension of its breast cancer tests as well as similar molecular
diagnostic products for colon cancer.

All of the abstracts listed below can currently be found
online at Presentation details are as follows (all times
are in Central Time).

Monday, June 6, 2011

Breast Cancer

1. Poster Presentation: Combined use of MammaPrint(R) and Molecular
Subtyping Profile (BluePrint(TM)) identifies subgroups with marked
differences in response to neo-adjuvant treatment.

- Lead Author: F. de Snoo, P. Roepman, O. Krijgsman, R.A.
, R. Bernards, A. Glas

- Presentation Time: 8:00 AM - 12:00 PM; Location: Hall A

2. Poster Presentation: A gene profile that identifies molecular subtypes
of breast cancer is highly enriched in genes having Estrogen Receptor binding

- Lead Author: W. Zwart, F. De Snoo, O. Krijgsman, P. Roepman,
S. Tian, A. Glas, R.A. Bender, J. Carroll, R. Bernards

- Presentation Time: 1:00 PM - 5:00 PM; Location: Hall A

3. Poster Presentation: Correlation between miRNA and gene expression
profiles and response to neoadjuvant chemotherapy in patients with locally
advanced and inflammatory breast cancer.

- Lead Author: G. Somlo, S. M. Li, X. Wu, S. Lau, P. H. Frankel, L.
Kruper, H. Gao, G. Sun, J.H. Yim, A. Hurria, J. E. Mortimer, F. De Snoo, I.B.
, J. Rossi, E. Wang, P. Roepman, Y. Yen, L. van't Veer, R. A. Bender

- Presentation Time: 1:00 PM - 5:00 PM; Location: Hall A

4. Publication-only Abstract: Comparison of MammaPrint(R) and
TargetPrint(R) with clinical parameters in patients with breast cancer:
Findings from a prospective U.S. cohort.

- Lead Author: K. B. Deck, R. Sinha, D. Kerlin, J. Barone, E.
Rivera, A. A. Garcia, K. Yao, L. Stork-Sloots, R. A. Bender, B. Nguyen

Colorectal Cancer

5. Poster Presentation: The PARSC trial, a prospective study for the
assessment of recurrence risk in stage II colon cancer (CC) patients using

- Lead Author: Salazar R, Rosenberg R, Lutke Holzik M, Marshall
J, van der Hoeven K, Glimelius B, Bibeau, F.

- Presentation Time: 8:00 AM - 12:00 PM; Location: Hall A

6. Poster Presentation & Discussion: The role of activating mutations of
KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and
prediction of treatment response to cetuximab in colorectal cancer.

- Lead Author: I. Simon, S. Tian, V. Moreno, P. Roepman, J.
Tabernero, M. Snel, T. Macarulla, L. van't Veer, R. Bernards, G. Capella

- Presentation Time: 8:00 AM - 12:00 PM; Discussion Time: 11:30 AM
to 12:30 PM
; Location: Hall D1

About Agendia

Agendia is an innovative molecular diagnostic company, striving to bring
more effective, individualized treatments within reach of patients. Building
on a genomics platform for tumour gene expression profiling, the company's
tests help physicians more accurately select a course of cancer treatment for
their patients. Agendia markets four products, with several new genomic tests
under development. In addition, Agendia collaborates with pharmaceutical
companies to develop companion diagnostic tests in the area of oncology.
Agendia is based in Amsterdam, the Netherlands and in Irvine, California. For
more information, please visit

    For further information, please contact:

    Dr. Bernhard Sixt, President & CEO
    International media and investor enquiries

    Mary-Jane Elliott / Emma Thompson
    Tel: +44(0)20-7920-2345, E-mail:

    Dutch media enquiries
    Huijskens Communications
    Ian Bickerton
    Tel: +31(0)20-685-5955, E-mail:

    US Media enquiries
    Ricochet Public Relations
    Valerie Carter
    Tel: +1-202-316-0143, E-mail:


will not be displayed